Skip to ContentSkip to Navigation
Rijksuniversiteit Groningenfounded in 1614  -  top 100 university
Over ons Praktische zaken Waar vindt u ons dr. S.P.C. Lam

Publicaties

Effects of Finerenone on Readmissions for Heart Failure: Insights From the FINEARTS-HF Trial

Finerenone and New York Heart Association Functional Class in Heart Failure: The FINEARTS-HF Trial

Timing of Cardiovascular and Kidney Benefits With Finerenone in Heart Failure and Chronic Kidney Disease With Type 2 Diabetes

Achieved Ejection Fraction and Effects of Dapagliflozin in Heart Failure With Improved Ejection Fraction

Anaemia in patients with heart failure and mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS-HF trial

Anthropometric Measures, Cardiovascular Outcomes, and Treatment Effects of Finerenone in Cardiovascular-Kidney-Metabolic Disease: Pooled Participant-Level Analysis of 3 Global Trials

Assessing Benefit in Patients With Heart Failure and Reduced Ejection Fraction: Analysis of the VICTORIA Trial Using Novel Prognostic Risk Stratification

Authors’ reply to quality of care delivery in patients with acute heart failure

Baseline characteristics of contemporary trial participants with heart failure and reduced ejection fraction: The VICTOR trial

Blinded Withdrawal of Finerenone After Long-Term Treatment in the FINEARTS-HF Trial

Pers/media

Journal of Cardiac Failure Launches Rapid Publication Platform to Spark Discourse

Wat is nieuw in de 2021 ESC HF richtlijn wat betreft patiënten met EF>40%?